Studies have examined the differences in sociodemographic/clinical characteristics between patients on long-acting injectable (LAI) versus oral medications. However, most studies did not focus specifically on patients for whom LAIs would clearly be indicated. We performed a chart review of patients with schizophrenia or schizoaffective disorder. Patients were categorized as having an 'indication for an LAI' or not on the basis of their adherence history. Patients for whom an LAI was indicated and prescribed on discharge were then compared with similar patients for whom an LAI was not prescribed. Of 305 charts reviewed, consisting of 279 unique patients, 27.2% were judged to have an indication for an LAI (n=76), but only 32.9% of these (n=25) were discharged on an LAI. In the multiregression model, being African American, residing in a psychiatric residence, having a previous history of an LAI trial, and being treated with a higher antipsychotic dose were predictive of LAI prescription. It is important to focus on the population who are not likely to receive an LAI, but who have such indications for treatment.

中文翻译：

---

长效可注射抗精神病药的适应症和使用：从住院患者的角度考虑。

研究已经检查了长效注射（LAI）与口服药物治疗的患者在社会人口统计学/临床特征方面的差异。但是，大多数研究并没有专门针对那些明确指出需要LAI的患者。我们对精神分裂症或精神分裂症患者进行了图表审查。根据患者的依从史，将其归类为是否具有“ LAI适应症”。然后将指示有LAI并在出院时开具LAI的患者与未开具LAI的类似患者进行比较。在所审查的305张图表中，由279名独特患者组成，其中27.2％被判定具有LAI指征（n = 76），但其中只有32.9％（n = 25）因LAI出院。在多元回归模型中，是非裔美国人，居住在精神病院，有LAI试验的既往史并接受较高的抗精神病药物治疗可预示LAI处方。重要的是要集中于那些不太可能接受LAI但有这种适应症的人群。